Hyaluronan derivative Hymovis® increases cartilage volume and type II collagen turnover in osteoarhritic knee: data from Mokha study

Y Henrotin,C Confavreux,J Bentin,D Urbin-Choffray,P Thomas,N Giordan,H.-K Ea,A Marinello,R Bannuru,J.-P Brasseur,P Richette,T Conrozier,M Malaise

doi:10.1016/j.joca.2018.02.582

Abstract

Hyaluronan derivative Hymovis® increases cartilage volume and type II collagen turnover in osteoarhritic knee: data from Mokha study

Highlights

PGF2a, PGD2 and TXB2 was determined quantitatively by specific ELISAs
Since intra-articular administration of celecoxib means that the drug will interact with different intra-articular tissues such as the cartilage, synovium, Hoffa's Fat Pad (HFP) and meniscus we first evaluated the ability of celecoxib to modulate prostanoid release from these intra-articular tissues
We investigated whether prostanoid-reducing actions of celecoxib on different intraarticular tissues is accompanied by a modulation of the expression of aggrecanases, which are important proteolytic enzymes involved in OA pathophysiology

Summary

Introduction

PGF2a, PGD2 and (thromboxane B2) TXB2 was determined quantitatively by specific ELISAs. CELECOXIB MODULATES RELEASE OF DIFFERENT PROSTANOID SUBTYPES BY INTRA-ARTICULAR TISSUES: TOWARDS CELECOXIB BASED INTRA-ARTICULAR TREATMENT FOR OA MODULATION? In this study we hypothesized that celecoxib can be used as an OA-modulatory drug when injected intra-articularly in the knee joint.

Results

Conclusion